L’Oreal to Acquire Majority Stake in Skincare Brand Medik8

French cosmetics giant L’Oreal has announced plans to acquire a majority stake in British skincare brand Medik8, aiming to expand its Luxe portfolio. The deal highlights L’Oreal’s strategy to invest in high-performance, science-backed beauty brands that offer accessibility and global growth potential.

Medik8, known for its clinically proven skincare products and affordable pricing, has gained popularity among consumers seeking effective yet reasonably priced solutions. L’Oreal sees strong international potential in the brand and believes its addition will further diversify and strengthen its premium beauty segment.

The transaction is expected to close within the coming months, pending regulatory approvals and customary closing conditions. While financial terms were not disclosed, the acquisition aligns with L’Oreal’s long-term growth ambitions in the luxury skincare market.

As part of the agreement, private equity firm Inflexion will retain a minority stake in Medik8. The brand’s founder, scientist Elliot Isaacs, will remain on the board, and the existing management team will continue to lead operations. This continuity is expected to preserve the brand's innovation-driven culture and product development strategy.

L’Oreal has also secured rights to acquire the remaining shares in the future. The company will start including Medik8’s financials in its earnings reports once the deal is finalized.

This acquisition underscores L’Oreal’s commitment to expanding its portfolio with brands that resonate with modern skincare consumers and reflect current industry trends in science, sustainability, and efficacy. By integrating Medik8, L’Oreal positions itself to capture a larger share of the fast-growing dermocosmetic and luxury skincare markets globally.